Stifel – so far - is on the hook for more than $166 million in damages, legal fees and settlements in investor complaints ...

Chuck Roberts, who advocated a structured-notes strategy to some clients, has been the subject of 31 customer complaints ...

Some investors recently have seen million dollar plus decisions by FINRA arbitration panels involving complex products ...

Panelists on a FINRA arbitration board cited Randy Anderson's claims of age discrimination when questioning UBS's reasons for ...

"I've always really enjoyed what I do," said Henry, who began doing legal work involving municipal securities in 1981.

FINRA published today the 2025 FINRA Industry Snapshot, the annual statistical report on registered representatives, brokerage firms and market activity that ...

FINRA published today the 2025 FINRA Industry Snapshot, the annual statistical report on registered representatives, brokerage firms and market activity that FINRA oversees.

Investing.com - Stifel raised its price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $123.00 from $94.00 while maintaining a Buy rating on the stock. The company, currently valued at $5.5 ...

In the latest quarter, 4 analysts provided ratings for Stifel Financial SF, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates ...

Stifel maintains a positive bias towards Philip Morris due to its multi-category approach, which focuses on smoke-free products.

Paul Kilfoy has joined Bank of America Merrill Lynch as director, senior sales trader. The move sees Toronto-based Kilfoy join the firm from Stifel, where he had worked for almost five years. During ...